Allergan 10-Q2016 Q3 Quarterly report

Filed: 4 Nov 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: acid, Adare, Akarna, Androderm®testosterone, antibody, arm, Ascaol, autoimmune, Beneficial, Brazikumab, Cenicriviroc, commercilization, complementary, complemented, Coupon, Crohn, deficiency, degree, detected, deterioration, diabetic, differentiated, discovered, diversity, earliest, effort, elevated, Evogliptin, expansion, Extinguishment, fibrotic, ForSight, gamma, gene, ghrelin, Grow, IIb, impracticable, inflammation, inflammatory, inhibition, inhibitor, instrument, Interlocutory, Ireland, liver, mcg, MedImmune, metabolic, misstatement, modified, monoclonal, NASH, orphan, past, Pigmentosa, potent, Predominance, Prepayment, PTAB, ready, reassessing, redeployment, regular, relamorelin, repaying, restore, retinoic, retrosense, ring, RORyt, scope, Securitization, Tobira, ulcerative, vision, Vitae

Removed: accept, adequately, affiliate, agree, al, Alabama, Alaska, alendronate, Alpharma, answered, anticompetitive, appealing, Atlantic, audit, awarded, AWP, back, Bayer, BP, British, buying, Carolina, cease, ceasing, certiorari, cGMP, Chief, CIII, Cipro, ciprofloxacin, CMS, Cobalt, Commerce, commitment, committee, compensatory, competitor, compliance, comply, conduct, conducted, conducting, controlling, coordinated, Corona, damage, decree, defended, DESI, distribute, documentation, DOJ, education, Efficacy, eleven, Eleventh, emergency, Endo, Energy, entirety, ER, establish, examine, exceeding, excessive, exempted, exhausted, expert, failed, falsely, fee, found, FTC, gather, Georgia, GlaxoSmithKline, grid, GSK, guilty, hear, hired, hold, House, hydrochloride, Idaho, importing, imposing, incur, indemnification, indemnify, informed, initiating, inspection, inspectional, insufficient, investigating, investigatory, Judicial, jury, Justice, Kentucky, Kingdom, knowledge, learned, led, lidocaine, Lidoderm, line, listing, London, Louisiana, Magistrate, Mallinckrodt, Mckenzie, metformin, metoclopramide, mg, Morgan, Multidistrict, Nevada, niche, nonpublic, Northern, offering, Oklahoma, Opana, oxymorphone, paroxetine, periodic, permanent, personnel, pioglitazone, Pliva, promptly, propoxyphene, purporting, purpose, pursue, question, recalculate, recalculation, recalling, recommend, recommended, reliable, remedy, remove, remuneration, representing, responsibility, resubmission, reversed, revolver, Romanian, Rugby, seal, sham, show, Solvay, South, sponsorship, Study, substance, successfully, support, Supreme, tangible, Tennessee, thousand, training, transdermal, transferred, UK, undertaken, Union, unrelated, unused, verdict, Virginia, voluntary, WAC, West, wide, writ

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Allergan similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. of Section 1350, as Adopted by

Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned officer of Allergan plc and Warner Chilcott Limited (the “Companies”), hereby certifies, to such officer’s knowledge, that:

(i) the Quarterly Report on Form 10-Q of the Companies for the quarter ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Companies.

Date: November 4, 2016

By:		/s/ BRENTON L. SAUNDERS
		Brenton L. Saunders
		President and Chief Executive Officer
		(Principal Executive Officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.